Navkar Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 3.00 M
- Company Age 21 Year, 2 Months
- Last Filing with ROC 31 Mar 2020
- Satisfied Charges ₹ 2.50 M
- Revenue Growth %
- Profit Growth 14.12%
- Ebitda
- Net Worth -4.93%
- Total Assets -4.45%
About Navkar Drugs
Navkar Drugs Private Limited (NDPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 November 2003 and has a history of 21 years and two months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M.
The company has closed loans amounting to ₹2.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Kishansinh Solanki and Ishani Solanki serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231GJ2003PTC043232
-
Company No.
043232
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Nov 2003
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Navkar Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kishansinh Solanki
|
Director | 01-Apr-2011 | Current |
|
Ishani Solanki
|
Director | 01-Apr-2011 | Current |
Financial Performance of Navkar Drugs.
Navkar Drugs Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 14.12% increase in profit. The company's net worth dipped by a decrease of 4.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Navkar Drugs?
In 2017, Navkar Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Labdhi Logical Financial Solutions LlpKishansinh Solanki is a mutual person
-
Sinh Records Llp
Kishansinh Solanki is a mutual person
-
Om-Earth Realty Private Limited
Kishansinh Solanki and Ishani Solanki are mutual person
Charges (Loans)
₹0
₹2.50 M
Charges Breakdown by Lending Institutions
- Punjab National Bank : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Apr 2006 | Punjab National Bank | ₹2.50 M | Satisfied |
How Many Employees Work at Navkar Drugs?
Unlock and access historical data on people associated with Navkar Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Navkar Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Navkar Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
